Poster Session A - Sunday Afternoon
Category: Colon
Darren M. Brenner, MD, FACG
Northwestern University Feinberg School of Medicine
Chicago, IL
Placebo (N=359)a n(%) | Naloxegol 12.5 mg (N=352)a n(%) | Naloxegol 25 mg (N=331)a n(%) | Naloxegol 12mg vs. Placebo OR (95% CI) p-value | Naloxegol 25 mg vs. Placebo OR (95% CI) p-value |
Proportion of PAC-SYM Responders Achieving MCID ≥ 0.5 | ||||
207 (57.66%) | 231 (65.63%) | 230 (69.49%) | 1.501 (1.085, 2.078) 0.0143 | 1.776 (1.263, 2.497) 0.0010 |
Proportion of PAC-SYM Responders Achieving MCID ≥ 0.8 | ||||
152 (42.34%) | 161 (45.74%) | 177 (53.47%) | 1.217 (0.879, 1.687) 0.2368 | 1.709 (1.216, 2.401) 0.0020 |
aNumber of analyzable subjects with complete PAC-SYM data for 12-wks PAC-SYM, Patient Assessment of Constipation Symptoms questionnaire MCID, minimal clinically important difference OR, odds ratio CI, confidence interval |